2101 - CIBMTR SC21-07/BMT CTN 2101 Observational Study
-
- BMT CTN # 2101 Co-Chair: Joshua Hill, MD
- BMT CTN # 2101 Co-Chair: Miguel-Angel Perales, MD
- BMT CTN # 2101 Co-Chair: Marcie Riches, MD, MS
- BMT CTN # 2101 Protocol Officer: Mary Horowitz, MD, MS, MACP
- BMT CTN # 2101 Protocol Coordinator: TBD; bmtctn2101@emmes.com
|
NCT011660099 |
RECRUITING |
2002 - BMT CTN SR-aGVHD
- Protocol Short Name and Number: SR-aGVHD, 2002
- Protocol Long Name: A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
- Protocol Synopsis (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 2002 Co-Chair: John Levine, MD
- BMT CTN # 2002 Co-Chair: Gabby Meyers, MD
- BMT CTN # 2002 Co-Chair: Gérard Socié, MD
- BMT CTN # 2002 Protocol Officer: Mehdi Hamadani, MD
- BMT CTN # 2002 Protocol Coordinator: DJ White; 2002DCC@emmes.com
|
NCT04934670 |
RECRUITING |
2001 - SCD Gene Therapy
- Protocol Short Name and Number: SCD Gene Therapy/GRASP, 2001
- Protocol Long Name: A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 2001 Co-Chair: David Williams, MD
- BMT CTN # 2001 Co-Chair: Mark Walters, MD
- BMT CTN # 2001 Protocol Officer: Mary Eapen, MD
- BMT CTN # 2001 Protocol Coordinator: <TBD>; bmtctn2001@emmes.com
|
NCT05353647 |
NOT YET RECRUITING |
1905 - ITN077AI BEAT-MS
- Protocol Short Name and Number: BEAT-MS, 1905
- Protocol Long Name: A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing
- Key Personnel
-
- BMT CTN 1905 Co-Chair: Jeffrey A. Cohen, MD
- BMT CTN 1905 Co-Chair: George E. Georges, MD
- BMT CTN 1905 Co-Chair: Paolo A. Muraro, MD, PhD
- BMT CTN 1905 Chair: Marcelo Pasquini, MD; mpasquini@mcw.edu
- NIAID Protocol Coordinator: Sean McCarthy, RN, MS; sean.mccarthy@nih.org
- BMT CTN DCC Coordinator: Amy Foley; afoley@nmdp.org
Note: For the ITN077AI / BMT CTN 1905 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via NIAID/Immune Tolerance Network (ITN). BMT CTN Centers will receive both NIAID/ITN and BMT CTN accrual credits. For questions about the study and how to participate or to access study materials, contact the NIAID protocol coordinator, Sean McCarthy, at sean.mccarthy@nih.gov.
|
NCT04047628 |
RECRUITING |
1904 - Treosulfan for BMFD
-
- BMT CTN # 1904 Co-Chair: Lauri Burroughs, MD
- BMT CTN # 1904 Co-Chair: Margaret MacMillan, MD, MSc
- BMT CTN # 1904 Protocol Officer: Mehdi Hamadani, MD
- BMT CTN # 1904 Protocol Coordinator: Megan Scott; bmtctn1904@emmes.com
|
NCT04965597 |
RECRUITING |
1903 - HIV T-Cell
- Protocol Short Name and Number: HIV T-cell, 1903
- Protocol Long Name: (AMC-109) - Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 1903 Co-Chair: Rich Ambinder, MD
- BMT CTN # 1903 Co-Chair: Kieron Dunleavy, MD
- BMT CTN # 1903 Protocol Officer: Steve Devine, MD
- BMT CTN # 1903 Protocol Coordinator: Christine Borchert; bmtctn1903@emmes.com
|
NCT04975698 |
RECRUITING |
1902 - MM CAR-T to Upgrade Response
- Protocol Short Name and Number: MM CAR-T to Upgrade Response, 1902
- Protocol Long Name: Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 1902 Co-Chair: Sergio Giralt, MD
- BMT CTN # 1902 Co-Chair: Alfred Garfall, MD
- BMT CTN # 1902 Protocol Sponsor: Marcelo Pasquini, MD
- BMT CTN # 1902 Protocol Coordinator: Megan Scott; bmtctn1902@emmes.com
|
NCT05032820 |
RECRUITING |
1802 - T-Guard in SR-aGVHD
- Protocol Short Name and Number: T-Guard for SR aGVHD, 1802
- Protocol Long Name: An Open-Label, Single-Arm, Multicenter Study of Combination anti- CD3/CD7 Immunotoxin (T-Guard) for Steroid-Refractory Acute Graft- versus-Host Disease
- Protocol Synopsis (PDF)
- Key Personnel
-
- BMT CTN # 1802 Co-Chair: John Levine, MD
- BMT CTN # 1802 Co-Chair: Gabrielle Meyers, MD
- BMT CTN # 1802 Protocol Officer: Mehdi Hamadani, MD
|
NCT04128319 |
TERMINATED |
1706 - SWOG S1803 MM Maintenance
- Protocol Short Name and Number: SWOG S1803 MM Maintenance, 1706
- Protocol Long Name: Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
- Key Personnel
-
- BMT CTN # 1706 Chair: Parameswaran Hari, MD, MRCP
- BMT CTN # 1706 Protocol Coordinator: Cynthia Smith; csmith@swog.org
Note: For the SWOG S1803 / BMT CTN 1706 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via their NCTN group. BMT CTN Centers will receive both NCTN and BMT CTN accrual credits. The protocol may be accessed through the CTSU website: https://www.ctsu.org/. For questions about the study and how to participate, contact the SWOG protocol coordinator, Cynthia Smith, at csmith@swog.org or the CTSU Help Desk at ctsucontact@westat.com or 1 888 823-5923.
|
NCT04071457 |
RECRUITING |
1705 - AAT GVHD Treatment
- Protocol Short Name and Number: AAT GVHD Treatment, 1705
- Protocol Long Name: A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 – Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # Co-Chair: Amin Alousi
- BMT CTN # Co-Chair: John Magenau
- Protocol Officer: Mehdi Hamadani, MD
- Protocol Coordinator: Lindsey Haroun; bmtctn1705@emmes.com
|
NCT04167514 |
RECRUITING |
1704 - CHARM
- Protocol Short Name and Number: CHARM, 1704
- Protocol Long Name: Composite Health Assessment Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 1704 Co-Chair: Andrew Artz, MD
- BMT CTN # 1704 Co-Chair: Mohamed Sorror, MD, MSc
- BMT CTN # 1704 Protocol Officer: Wael Saber, MD, MS
- BMT CTN # 1704 Protocol Coordinator: Bailey Protz; bmtctn1704@nmdp.org
|
NCT03992352 |
ACTIVE, NOT RECRUITING |
1703-1801 - PROGRESS III - PTCY vs. TAC/MTX
- Protocol Short Name and Number: PROGRESS III – PTCY vs. TAC/MTX / Mi-Immune, 1703/1801
- Protocol Long Name:
-
- BMT CTN 1703: A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
- BMT CTN 1801: Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)
-
- BMT CTN # 1703 Co-Chair: Shernan Holtan, MD
- BMT CTN # 1703 Co-Chair: Javier Bolanos-Meade, MD
- BMT CTN # 1703 Protocol Officer: Mehdi Hamadani, MD
- BMT CTN # 1703 Protocol Coordinator: Kristy Applegate, MBA; bmtctn1703@emmes.com
- Key Personnel (BMT CTN 1801)
-
- BMT CTN # 1801 Co-Chair: Miguel-Angel Perales, MD
- BMT CTN # 1801 Co-Chair: Leslie Kean, MD, PhD
- BMT CTN # 1801 Co-Chair: Ami Bhatt, MD, PhD
- BMT CTN # 1801 Protocol Officer: Wael Saber, MD, MS
- BMT CTN # 1801 Protocol Coordinator: Kristy Applegate, MBA; bmtctn1703@emmes.com
|
NCT03959241 |
ACTIVE, NOT RECRUITING |
1702 - Donor Cell Cohort
- Protocol Short Name and Number: CTRL-ALT-D, 1702
- Protocol Long Name: Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 1702 Co-Chair: Stephanie Lee, MD
- BMT CTN # 1702 Co-Chair: Stefan Ciurea, MD
- BMT CTN # 1702 Protocol Officer: Bronwen Shaw, MD, PhD
- BMT CTN # 1702 Protocol Coordinator: Jenny Vogel; bmtctn1702@nmdp.org
|
NCT03904134 |
ACTIVE, NOT RECRUITING |
1601 - ECOG-ACRIN EA4151 MCL
- Protocol Short Name and Number: ECOG-ACRIN EA4151 MCL, 1601
- Protocol Long Name: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
- Key Personnel
-
- BMT CTN # 1601 Protocol Chair: Timothy Fenske, MD
- BMT CTN # 1601 Chair: Matthew Lunning, MD
- BMT CTN # 1601 Protocol Coordinator: Christiana Samuel, csamuel@ecog-acrin.org
- BMT CTN # 1601 Protocol Coordinator: Amy Foley, afoley@nmdp.org
Note: For the ECOG-ACRIN EA4151/BMT CTN 1601 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via their NCTN group. BMT CTN Centers will receive both NCTN and BMT CTN accrual credits. The protocol may be accessed through the CTSU website: https://www.ctsu.org For questions about the study and how to participate, contact the ECOG-ACRIN protocol coordinator, Haleigh Wetzel, at hwetzel@ecog-acrin.org or 857-504-2900, or the CTSU Help Desk at ctsucontact@westat.com or 1 888 823-5923.
|
NCT03267433 |
RECRUITING |
1507 - Haplo Sickle Cell
- Protocol Short Name and Number: Haplo Sickle Cell, 1507
- Protocol Long Name: Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease.
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 1507 Co-Chair: Michael DeBaun, MD
- BMT CTN # 1507 Co-Chair: Mark Walters, MD
- BMT CTN # 1507 Co-Chair: Adetola Kassim, MD
- BMT CTN # 1507 Co-Chair: Robert Brodsky, MD
- BMT CTN # 1507 Protocol Officer: Mary Eapen, MD, MS
- BMT CTN # 1507 Protocol Coordinator: Delisha Crawford, bmtctn1507@emmes.com
|
NCT03263559 |
RECRUITING |
1506 - AML FLT3 Maintenance Therapy
- Protocol Short Name and Number: AML FLT3 Maintenance Therapy, 1506
- Protocol Long Name: A multi-center, randomized, double-blind, placebo-controlled Phase III trial of the FLT3 inhibitor gilteritinib administered as maintenance therapy following allogeneic transplant for patients with FLT3/ITD AML
- Protocol (PDF)
- Key Personnel
-
- BMT CTN # 1506 Co-Chair: Mark Levis, MD
- BMT CTN # 1506 Co-Chair: Yi-Bin Chen, MD
- BMT CTN # 1506 Protocol Officer: Mehdi Hamadani, MD
- BMT CTN # 1506 Protocol Coordinator: Heather Wittsack and DJ White; 1506DCC@emmes.com
|
NCT02997202 |
ACTIVE, NOT RECRUITING |
1505 - RECRUIT
A Randomized Recruitment Intervention Trial.
This study is posted on clinicaltrials.gov as NCT01911208
Key Personnel
|
NCT01911208 |
COMPLETED |
1503 - STRIDE2
- Protocol Short Name and Number: STRIDE2, 1503
- Protocol Long Name: A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 1503 Co-Chair: Lakshmanan Krishnamurti, MD
- BMT CTN # 1503 Co-Chair: Mark Walters, MD
- BMT CTN # 1503 Protocol Officer: Mary Eapen, MD, MS
- BMT CTN # 1503 Protocol Coordinator: Delisha Crawford; bmtctn1503@emmes.com
|
NCT02766465 |
ACTIVE, NOT RECRUITING |
1502 - CHAMP
- Protocol Short Name and Number: CHAMP, 1502
- Protocol Long Name: Optimizing Haploidentical Aplastic Anemia Transplantation (CHAMP)
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 1502 Co-Chair: Michael (Mike) Pulsipher, MD
- BMT CTN # 1502 Co-Chair: Amy DeZern, MD, MS-HS
- BMT CTN # 1502 Protocol Officer: Mary Eapen, MD
- BMT CTN # 1502 Protocol Coordinator: Kristy Applegate; bmtctn1502@emmes.com
|
NCT02918292 |
ACTIVE, NOT RECRUITING |
1501 - SR aGVHD |
NCT02806947 |
COMPLETED |
1401 - Myeloma Vaccine
- Protocol Short Name and Number: Myeloma Vaccine, 1401
- Protocol Long Name: A Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma Fusions
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 1401 Co-Chair: David Avigan MD
- BMT CTN # 1401 Co-Chair: Nina Shah, MD
- BMT CTN # 1401 Co-Chair: David Chung, MD
- BMT CTN # 1401 Protocol Officer: Marcelo Pasquini, MD
- BMT CTN # 1401 Protocol Coordinator: Nicole Ritzau, RN; bmtctn1401@emmes.com
|
NCT02728102 |
COMPLETED |
1304 - DFCI 10-106 Myeloma |
NCT01208662 |
ACTIVE, NOT RECRUITING |
1302 - Allo Myeloma
- Protocol Short Name and Number: Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma, 1302
- Protocol Long Name: Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 1302 Co-Chair: Qaiser Bashir, MD
- BMT CTN # 1302 Co-Chair: Taiga Nishihori, MD
- BMT CTN # 1302 Co-Chair: Parameswaran Hari, MD
- BMT CTN # 1302 Protocol Officer: Marcelo Pasquini, MD, MS
- BMT CTN # 1302 Protocol Coordinator: Kristy Applegate; bmtctn1302@emmes.com
|
NCT02440464 |
COMPLETED |
1301 - CNI-free GVHD (PROGRESS II)
- Protocol Short Name and Number: CNI-free GVHD (PROGRES II), 1301
- Protocol Long Name: A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 1301 Co-Chair: Miguel-Angel Perales, MD
- BMT CTN # 1301 Co-Chair: Leo Luznik, MD
- BMT CTN # 1301 Protocol Officer: Marcelo Pasquini, MD, MS
- BMT CTN # 1301 Protocol Coordinator: Kristy Applegate, MBA; bmtctn1301@emmes.com
|
NCT02345850 |
COMPLETED |
1205 - ETRIC |
NCT02081248 |
COMPLETED |
1204 - RICHI |
NCT01998633 |
COMPLETED |
1203 - GVHD Prophylaxis (PROGRESS I) |
NCT02208037 |
COMPLETED |
1202 - Biomarkers |
NCT01879072 |
COMPLETED |
1201 - Alliance A051301 DLBCL |
NCT02443077 |
RECRUITING * |
1102 - MDS
- Protocol Short Name and Number: RIC vs Hypometh for MDS, 1102
- Protocol Long Name: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 1102 Co-Chair: Corey Cutler, MD, MPH, FRCP(C)
- BMT CTN # 1102 Co-Chair: Ryotaro (Ryo) Nakamura, MD
- BMT CTN # 1102 Protocol Officer: Wael Saber, MD, MS
- BMT CTN # 1102 Protocol Coordinator: Kristy Applegate; bmtctn1102@emmes.com
|
NCT02016781 |
ACTIVE, NOT RECRUITING |
1101 - Double Cord vs. Haplo
- Protocol Short Name and Number: Double cord vs. Haplo, 1101
- Protocol Long Name: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies
- Protocol (PDF)
- ICFs (PDF)
- FAQs (PDF)
- Key Personnel
-
- BMT CTN # 1101 Co-Chair: Ephraim Fuchs, MD
- BMT CTN # 1101 Co-Chair: Paul O’Donnell, MD, PhD
- BMT CTN # 1101 Co-Chair: Claudio Brunstein, MD
- BMT CTN # 1101 Protocol Officer: Mary Eapen, MD, MS
- BMT CTN # 1101 Protocol Coordinator: Nicole Ritzau, RN; bmtctn1101@emmes.com
|
NCT01597778 |
COMPLETED |
0903 - Allo Transplant in HIV |
NCT01410344 |
COMPLETED |
0902 - Peri-Transplant Stress Mgmt. |
NCT01278927 |
COMPLETED |
0901 - Full vs RIC in MDS/AML |
NCT01339910 |
TERMINATED |
0805 - SWOG 0805 ALL |
NCT00792948 |
ACTIVE, NOT RECRUITING |
0804 - Cancer and Leukemia Group B |
NCT01027000 |
ACTIVE, NOT RECRUITING |
0803 - Auto Transplant in HIV |
NCT01141712 |
COMPLETED |
0802 - aGVHD Phase III |
NCT01002742 |
COMPLETED |
0801 - cGVHD Treatment |
NCT01106833 |
COMPLETED |
07LT - 0702 LTFU |
NCT02322320 |
COMPLETED |
0704 - CALGB 100104 Myeloma |
NCT00114101 |
ACTIVE, NOT RECRUITING |
0703 - SCT Hodgkins |
NCT00233987 |
COMPLETED |
0702 - STaMINA (multiple myeloma) |
NCT01109004 |
COMPLETED |
0701 - Follicular NHL |
NCT00912223 |
COMPLETED |
0604 - NST Cord Blood |
NCT00864227 |
COMPLETED |
0603 - NST Haploidentical |
NCT00849147 |
COMPLETED |
0601 - Sickle Cell |
NCT00745420 |
COMPLETED |
0502 - NST for Elderly AML |
NCT00070135 |
COMPLETED |
0501 - Cord Blood |
NCT00412360 |
COMPLETED |
0403 - Etanercept IPS |
NCT00421174 |
COMPLETED |
0402 - GVHD Prophylaxis |
NCT00406393 |
COMPLETED |
0401 - Bexxar/BEAM |
NCT00329030 |
COMPLETED |
0303 - AML T-cell Depletion |
NCT00201240 |
COMPLETED |
0302 - Acute GVHD |
NCT00224874 |
COMPLETED |
0301 - Aplastic Anemia |
NCT00326417 |
COMPLETED |
0202 - Follicular Lymphoma |
NCT00096460 |
TERMINATED |
0201 - URD PB vs BM |
NCT00075816 |
COMPLETED |
0102 - Multiple Myeloma |
NCT00075829 |
COMPLETED |
0101 - Fungal Prophylaxis |
NCT00075803 |
COMPLETED |